CAR T cell therapy, originally developed to treat blood cancers by reprogramming immune cells, is now being tested in hundreds of clinical trials for autoimmune diseases including multiple sclerosis, lupus, and Graves' disease, with early results showing promise but raising questions about long-term safety and durability. The treatment works by removing a patient's T cells, engineering them to attack disease-causing B cells, and reinfusing them to reset the immune system.
Topicle Beta
1 comment
CAR T cell therapy, originally developed to treat blood cancers by reprogramming immune cells, is now being tested in hundreds of clinical trials for autoimmune diseases including multiple sclerosis, lupus, and Graves' disease, with early results showing promise but raising questions about long-term safety and durability. The treatment works by removing a patient's T cells, engineering them to attack disease-causing B cells, and reinfusing them to reset the immune system.